0001415889-24-009394.txt : 20240329
0001415889-24-009394.hdr.sgml : 20240329
20240329103909
ACCESSION NUMBER: 0001415889-24-009394
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240329
DATE AS OF CHANGE: 20240329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haddadin Yezan Munther
CENTRAL INDEX KEY: 0001718004
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 24802495
MAIL ADDRESS:
STREET 1: ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA
STREET 2: 4TH FLOOR, PO BOX 142904
CITY: AMMAN
STATE: M2
ZIP: 11844
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 485 ROUTE 1 SOUTH
STREET 2: BUILDING F, SUITE 320
CITY: ISELIN
STATE: NJ
ZIP: 08830
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
form4-03292024_020304.xml
X0508
4
2024-03-28
0001649989
Outlook Therapeutics, Inc.
OTLK
0001718004
Haddadin Yezan Munther
C/O OUTLOOK THERAPEUTICS, INC.
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320
ISELIN
NJ
08830
true
false
false
false
0
Common Stock
2024-03-28
4
P
0
1881.7112
11.82
A
5048.7112
D
The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024.
/s/ Lawrence Kenyon, Attorney-in-Fact
2024-03-29